MCL Literature Feed

Brexucabtagene autoleucel induced a durable 19-month remission in heavily pretreated MCL with intraocular relapse, demonstrating CAR-T efficacy in this rare sanctuary site.

White-centered retinal hemorrhages (Roth spots) can be the initial presenting sign of an otherwise hidden mantle cell lymphoma, highlighting an important and unusual diagnostic clue for clinicians.

This Danish nationwide study confirms blastoid morphology, high Ki67, and high CNS-IPI as key risk factors for secondary CNS lymphoma, supporting consideration of upfront CNS screening in high-risk patients.

This paper likely characterizes the clinical features, treatment patterns, and poor outcomes of isolated central nervous system relapse in MCL, highlighting a major unmet clinical need.

Ibrutinib monotherapy rapidly resolved bilateral intraocular MCL recurrence presenting as pseudo-uveitis and glaucoma, demonstrating its efficacy in this rare CNS sanctuary site relapse.

A rare case of co-existing CNS DLBCL and systemic MCL was successfully treated with a multi-modal approach including chemotherapy, ibrutinib bridging, and autologous transplant, achieving 3-year remission.

A case of Candida albicans meningoencephalitis in an MCL patient highlights the diagnostic challenge of CNS symptoms, underscoring the need to consider opportunistic fungal infections beyond CNS relapse.

This case report describes a rare MCL relapse presenting as diabetes insipidus due to CNS involvement of the hypothalamus, highlighting an unusual manifestation of extranodal disease.

This case report highlights the critical role of MRI in diagnosing post-CAR-T neurotoxicity in MCL, demonstrating findings like limbic encephalitis to differentiate ICANS from other CNS pathologies.

This case report demonstrates CNS relapse in an MCL patient with a low Ki-67 (10%), underscoring the need for CSF analysis in symptomatic patients regardless of proliferation index.

A case of ganciclovir-resistant CMV encephalitis in a pirtobrutinib-treated MCL patient highlights a rare but severe infectious complication, urging vigilance for CNS symptoms with this non-covalent BTKi.

This case report of a non-MCL conjunctival lymphoma notes that MCL is a rare cause, highlighting an uncommon site of extranodal disease for MCL patients.

This case report describes a rare MCL CNS relapse presenting as Horner syndrome and oculomotor nerve palsy, highlighting the need for CSF analysis in patients with atypical neurological symptoms, even with normal imaging.

This case report and literature review details the diagnosis and management of central nervous system involvement in MCL, a rare and aggressive manifestation with a poor prognosis.

This case report of non-nodal CNS MCL mimicking autoimmune or paraneoplastic encephalitis highlights the need to consider lymphoma in the differential diagnosis of complex neurological syndromes.

This first-reported case of sphenoid sinus MCL causing acute bilateral blindness demonstrates that prompt chemo-surgical intervention can partially reverse vision loss, highlighting a rare but critical CNS presentation.

This paper outlines the diagnostic and treatment challenges of rare ocular and nasopharyngeal MCL, highlighting the necessity of a multidisciplinary approach for managing these extranodal presentations.

This multicenter real-world study demonstrates that CAR-T therapy can be an effective treatment for MCL patients with secondary CNS involvement, a population with historically poor outcomes.

Bendamustine is a feasible alternative lymphodepletion for brexu-cel in MCL, showing comparable efficacy to standard cy/flu with less cytopenia, providing a critical option during drug shortages.

This case report details severe glofitamab-induced ICANS with seizures in a heavily pre-treated MCL patient, highlighting CNS risk factors and successful management with anakinra and antiseizure drugs.

Brexucabtagene autoleucel (CAR-T) combined with BTK inhibitors is a potentially safe and effective strategy for treating relapsed mantle cell lymphoma with central nervous system involvement.

Combining CAR-T therapy with a BTK inhibitor may offer a synergistic strategy to effectively treat mantle cell lymphoma with central nervous system involvement, a historically poor-prognosis population.

This case report describes a rare presentation of primary, localized orbital mantle cell lymphoma successfully managed with local excision and radiotherapy, highlighting an unusual clinical scenario for this systemic disease.

This case report demonstrates that filgrastim-induced HLH in an MCL patient can be managed by switching to lenograstim with steroid prophylaxis, allowing continuation of intensive chemotherapy.

This case report documents the first complete response of frontline CNS-involved MCL to single-agent acalabrutinib, suggesting a potential chemotherapy-free, CNS-penetrant option for this high-risk population.

This case of classical MCL rapidly transforming to a blastoid variant with CNS involvement highlights the poor prognosis and failure of BTKi and chemotherapy in this aggressive setting.

This case report details an extremely rare MCL presentation of bilateral hemorrhagic hypopyon, successfully treated with intravitreal rituximab, systemic chemotherapy, and radiation, expanding the differential for unusual ocular findings.